Innate Pharma receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia

• First randomized Phase II trial of the anti-KIR antibody IPH2102
• Led by French Cooperative Groups in AML and sponsored by Innate Pharma

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that it has received regulatory authorization to start a double-blind placebo-controlled randomized Phase II trial of IPH2102/BMS-986015 as maintenance treatment in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission (study IPH2102-201, the “EffiKIR” trial).